Alzheimer's Advocacy Group Pushes the FDA, Jefferies Reiterates Buy on Biogen (BIIB)
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $450.00 price target on Biogen (NASDAQ: BIIB) after a major Alzheimer's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
